DERWENT-ACC-NO: 1999-153313
DERWENT-WEEK: 200063
COPYRIGHT 1999 DERWENT INFORMATION LTD

TITLE: Diagnosis, treatment and prevention of diabetes and other autoimmune
diseases - using antibodies reactive with anti-T-cell receptor
Vbeta antibody

INVENTOR: MATOSSIAN-ROGERS, A

PATENT-ASSIGNEE: MATOSSIAN-ROGERS A[MATOI]

PRIORITY-DATA: 1998GB-0010676 (May 18, 1998) , 1997GB-0015281
(July 21, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	
PAGES	MAIN-IPC		
CN 1264426 A	August 23, 2000	N/A	000
C12N 015/09			
WO 9905175 A2	February 4, 1999	E	072
C07K 016/00			
AU 9884517 A	February 16, 1999	N/A	000
C07K 016/00			
EP 998556 A2	May 10, 2000	E	000
C12N 015/09			
BR 9810118 A	August 8, 2000	N/A	000
C07K 016/00			

DESIGNATED-STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ
DE DK EE ES FI G
B GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV
MD MG MK MN MW
MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN
YU ZW AT BE CH
 CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT
SD SE SZ UG ZW A
L AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI

APPLICATION-DATA:

PUB-NO	APPL-DESCRIPTOR	APPL-NO
APPL-DATE		
CN 1264426A	N/A	1998CN-0807380
July 20, 1998		
WO 9905175A2	N/A	1998WO-GB02151
July 20, 1998		

```
AU 9884517A        N/A                   1998AU-0084517
July 20, 1998
AU 9884517A        Based on              WO 9905175
N/A
EP 998556A2        N/A                   1998EP-0935160
July 20, 1998
EP 998556A2        N/A                   1998WO-GB02151
July 20, 1998
EP 998556A2        Based on              WO 9905175
N/A
BR 9810118A        N/A                   1998BR-0010118
July 20, 1998
BR 9810118A        N/A                   1998WO-GB02151
July 20, 1998
BR 9810118A        Based on              WO 9905175
N/A
```

INT-CL (IPC): A61K038/16; A61K039/395 ; C07K014/435 ;
C07K016/00 ;
C07K016/42 ; C12N015/09

RELATED-ACC-NO: 1999-073525

ABSTRACTED-PUB-NO: WO 9905175A
BASIC-ABSTRACT: Use as a pharmaceutical or diagnostic reagent of
one of the
following is new: (a) mono- or poly-clonal antibodies (Ab1), or
equivalent
ligand, reactive with an anti-TCR (T-cell receptor) V beta
antibody (Ab2); (b)
(oligo- or poly-)peptide or protein (I), bound to Ab1, or its
equivalent
ligand, that is not Ab2; (c) genomic DNA, cDNA or RNA (II)
encoding Ab1,
equivalent ligand or (I); (d) bacteriophage clone, plasmid or
viral vector
containing (II), designated (IIa), that encodes the ESRP1 protein
(endocrine
secretion regulatory protein). Also new are (1) any (I),
designated (Ia),
containing the ESRP1 sequence (of 410 amino acids, given in the
specification);
(2) any nucleic acid (IIa) encoding ESRP1; (3) bacteriophage
clone, plasmid or
viral vector containing (IIa); (4) host cells stably transfected
or transformed
with a plasmid or vector of (3).

USE - Ab1, (I) or (Ia) are used to treat or prevent
(non-)insulin-dependent
diabetes mellitus, (non-)organ-specific autoimmune diseases,

cardiovascular
diseases, cachexia, cancer and generally any condition associated
with
anti-phospholipid (PL) antibodies, hyperinsulinaemia and insulin
resistance.
Ab1, and equivalent ligands, are also used to detect and quantify
natural
autoantibodies (Ab3) in blood, plasma and serum, for determining
susceptibility
to autoimmune disease and for prognosis of disease or treatment
efficiency.
The method is based on the idea that Ab3 are responsible for
autoimmune
diseases, e.g. in the case of diabetes they bind to proteins on
alpha -cells,
resulting in dysregulation of insulin secretion and then beta
-cell death.

CHOSEN-DRAWING: Dwg.0/7

TITLE-TERMS:
DIAGNOSE TREAT PREVENT DIABETES DISEASE ANTIBODY REACT ANTI CELL
RECEPTOR
ANTIBODY

DERWENT-CLASS: B04 D16 S03

CPI-CODES: B04-B04D4; B04-B04D5; B04-E02; B04-E03; B04-E08;
B04-F0100E;
B04-F1100E; B04-G01; B04-G21; B04-G22; B04-H01; B04-N04;
B11-C07A; B12-K04A;
B14-E11; B14-F01; B14-F02; B14-G02D; B14-H01; B14-S04; D05-H09;
D05-H10;
D05-H11; D05-H12A; D05-H12E; D05-H14; D05-H17A2;

CHEMICAL-CODES:
Chemical Indexing M1 *01*
    Fragmentation Code
    M423 M710 M903 P433 P520 P522 P631 P633 P816 P831
    Q233 V600 V611

Chemical Indexing M1 *02*
    Fragmentation Code
    M423 M710 M903 P433 P520 P522 P631 P633 P816 Q233
    V752 V901 V902

Chemical Indexing M1 *03*
    Fragmentation Code
    M423 M710 M903 Q233 V753

Chemical Indexing M1 *04*

Fragmentation Code
M423 M710 M903 N135 Q233 V500 V540 V560 V754

SECONDARY-ACC-NO:
CPI Secondary Accession Numbers: C1999-045200

```
RESULT    1
X22754
ID    X22754 standard; DNA; 1231 BP.
XX
AC    X22754;
XX
DT    07-JUN-1999  (first entry)
XX
DE    Human ESRP1 DNA.
XX
KW    ESRP1; treatment; prevention; non-insulin-dependent diabetes mellitus;
KW    non-organ-specific autoimmune disease; cardiovascular disease; cancer;
KW    cachexia; anti-phospholipid antibody; hyperinsulinaemia; T-cell receptor;
KW    insulin resistance; monoclonal; polyclonal; anti-TCR; V beta antibody;
KW    detection; autoantibody; blood; plasma; serum; autoimmune disease; human;
KW    alpha-cell; dysregulation; insulin secretion; beta-cell death; ss.
XX
OS    Homo sapiens.
XX
FH    Key              Location/Qualifiers
FT    CDS              1..1231
FT                     /*tag=  a
FT                     /product= "ESRP1"
FT                     /partial
FT                     /codon_start= 2
XX
PN    WO9905175-A2.
XX
PD    04-FEB-1999.
XX
PF    20-JUL-1998;   98WO-GB02151.
XX
PR    18-MAY-1998;   98GB-0010676.
PR    21-JUL-1997;   97GB-0015281.
XX
PA    (MATO/) MATOSSIAN-ROGERS A.
XX
PI    Matossian-Rogers A;
XX
DR    WPI; 1999-153313/13.
DR    P-PSDB; W93254.
XX
PT    Diagnosis, treatment and prevention of diabetes and other autoimmune
PT    diseases - using antibodies reactive with anti-T-cell receptor Vbeta
PT    antibody
XX
PS    Disclosure; Fig 6; 72pp; English.
XX
CC    This sequence encodes the human ESRP1 protein. This protein or
CC    antibody fragments generated from it are used to treat or prevent
CC    (non-)insulin-dependent diabetes mellitus, (non-)organ-specific
CC    autoimmune diseases, cardiovascular diseases, cachexia, cancer and
CC    generally any condition associated with anti-phospholipid antibodies,
CC    hyperinsulinaemia and insulin resistance. Mono- or poly-clonal antibodies
CC    and equivalent ligands reactive with an anti-TCR (T-cell receptor) V beta
CC    antibody are also used to detect and quantify natural autoantibodies in
CC    blood, plasma and serum, for determining susceptibility to autoimmune
```

```
CC   disease and for prognosis of disease or treatment efficiency. The method
CC   is based on the idea that autoantibodies are responsible for autoimmune
CC   diseases, e.g. in the case of diabetes they bind to proteins on
CC   alpha-cells, resulting in dysregulation of insulin secretion and then
CC   beta-cell death.
XX
SQ   Sequence 1231 BP; 287 A; 388 C; 362 G; 194 T; 0 other;
```

```
     Query Match              41.2%;  Score 1088.8;  DB 20;  Length 1231;
     Best Local Similarity    94.9%;  Pred. No. 1.4e-224;
     Matches 1198;  Conservative    0;  Mismatches   12;  Indels  52;  Gaps    5;


Qy    1359 ggatgaacagggccccatccgctgcaacaccacagtctgcctgggcaaaatcggctccta 1418
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      10 ggatgaacagggccccatccgctgcaacaccacagtctgcctgggcaaaatcggctccta 69


Qy    1419 cctcagtgctagcaccagacacagggtccttacctctgccttcagccgagccactaggga 1478
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      70 cctcagtgctagcaccagacacagggtccttacctctgccttcagccgagccactaggga 129


Qy    1479 cccgtttgcaccgtcccgggttgcgggtgtcctgggctttgctgccacccacaacctcta 1538
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     130 cccgtttgcaccgtcccgggttgcgggtgtcctgggctttgctgccacccacaacctcta 189


Qy    1539 ctcaatgaacgactgtgcccagaagatcctgcctgtgctctgcggtctcactgtagatcc 1598
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     190 ctcaatgaacgactgtgcccagaagatcctgcctgtgctctgcggtctcactgtagatcc 249


Qy    1599 tgagaaatccgtgcgagaccaggccttcaaggcatttcggagcttcctgtccaaattgga 1658
            |||||||||||||||||||||||||||||||||    |||||||||||||||||||||||
Db     250 tgagaaatccgtgcgagaccaggccttcaaggccattcggagcttcctgtccaaattgga 309


Qy    1659 gtctgtgtcggaggacccgacccagctggaggaagtggagaaggatgtccatgcagcctc 1718
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     310 gtctgtgtcggaggacccgacccagctggaggaagtggagaaggatgtccatgcagcctc 369


Qy    1719 cagccctggcatgggaggagccgcagctagctgggcaggctgggccgtgaccggggtctc 1778
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     370 cagccctggcatgggaggagccgcagctagctgggcaggctgggccgtgaccggggtctc 429


Qy    1779 ctcactcacctccaagctgatccgttcgcacccaaccactgccccaacagaaaccaacat 1838
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     430 ctcactcacctccaagctgatccgttcgcacccaaccactgccccaacagaaaccaacat 489


Qy    1839 tccccaaagacccacgcctgaaggagttcctgccccagccccacccctgttcctgccac 1898
            ||||||||||||||||||||||    ||||||||||||||||||||||||||||||||||
Db     490 tccccaaagacccacgcctga---agttcctgccccagcccccacccctgttcctgccac 546


Qy    1899 ccctacaacctcaggccactgggagacgcaggaggaggacaaggacacagcagaggacag 1958
            |||||||||||||||||||||||||||||||||||||||||||||||||||||| |||||
Db     547 ccctacaacctcaggccactgggagacgcaggaggaggacaaggacacagcagaagacag 606


Qy    1959 cagcactgctgacagatgggacgacgaagactggggcagcctggagcaggaggccgagtc 2018
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     607 cagcactgctgacagatgggacgacgaagactggggcagcctggagcaggaggccgagtc 666
```

```
Qy   2019 tgtgctggcccagcaggacgactggagcaccggggggccaagtgagccgtgctagtcaggt 2078
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    667 tgtgctggcccagcaggacgactggagcaccggggggccaagtgagccgtgctagtcaggt 726

Qy   2079 cagcaactccgaccacaaatcctccaaatccccagagtccgac-tggagcagctgggaag 2137
          |||||||||||||||||||||||||||||||||||||||||| ||||||| |||||||||
Db    727 cagcaactccgaccacaaatcctccaaatccccagagtccgacttggagcaactgggaag 786

Qy   2138 ctgagggctcctgggaacagggctggcaggagccaagctcccaggagccaccttctgacg 2197
          || | || |||| |||
Db    787 cttaagggtccttgga-------------------------------------------- 802

Qy   2198 gtacacggctggccagcgagtataactggggtggcccagagtccagcgacaagggcgacc 2257
           ||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||
Db    803 --acacggctggccagcgagtataactggggttgcccagagtccagcgacaagggcgacc 860

Qy   2258 ccttcgctaccctgtctgcacgtcccagcacccagccgaggccagactcttggggtgagg 2317
          |||||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||
Db    861 ccttcgctaccctgtctgcacgttccagcacccagccgaggccagactcttggggtgagg 920

Qy   2318 acaactgggagggcctcgagactgacagtcgacaggtcaaggctgagctggcccggaaga 2377
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    921 acaactgggagggcctcgagactgacagtcgacaggtcaaggctgagctggcccggaaga 980

Qy   2378 agcgcgaggagcggcggcgggagatggaggccaaacgcgccgagaggaaggtggccaagg 2437
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    981 agcgcgaggagcggcggcgggagatggaggccaaacgcgccgagaggaaggtggccaagg 1040

Qy   2438 gccccatgaagctgggagcccggaagctggactgaaccgtggcggtggcccttcccggct 2497
          |||||||||||||||||||||||||||||| |||||||||||||||||||||||||||||
Db   1041 gccccatgaagctgggagcccggaagctgga-tgaaccgtggcggtggcccttcccggct 1099

Qy   2498 gcggagagcccgccccacagatgtatttattgtacaaaccatgtgagcccggccggccca 2557
          ||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||
Db   1100 gcggagagcccgccccacagatgtatttattgtacaaaccatgtgaggccggccggccca 1159

Qy   2558 gccaggccatctcacgtgtacataatcagagccacaataaattctatttcacaaaaaaaa 2617
          |||||||||| |||||||||||||||||||||||||||||||||| ||||||||||||||
Db   1160 gccaggccat-tcacgtgtacataatcagagccacaataaattttatttcacaaaaaaaa 1218

Qy   2618 aa 2619
          ||
Db   1219 aa 1220
```